Abstract
Adenosin diphospat (ADP) plays a crucial role in thrombus formation. Therefore its inhibition can control excess platelet generation to prevent cardiovascular events in patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI). One of ADP’s target receptors, P2Y12 has a limited tissue distribution and is therefore an attractive pharmacological target. Thienopyridines are class of drugs that specifically and irreversibly inhibit the P2Y12 receptor. Three generations exist and in most patients, they are administered in combination with aspirin. Because of possible gastro-intestinal toxicity, a proton pump inhibitor (PPI) is often concomitantly prescribed. However, several studies suspect an interaction between thienopyridines (in particular with clopidogrel) and PPIs which decreases the inhibition of platelet formation and thus enhances the risk for cardiac events. In this review, a concise overview of pharmacokinetic and pharmacodynamic properties of all thienopyridines is given and a critical discussion of the presumed interaction with PPIs is provided.
Keywords: Drug-eluting stent, stent thrombosis, thienopyridines, proton pump inhibitors.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Interaction between Thienopyridines and Proton Pump Inhibitors
Volume: 14 Issue: 3
Author(s): Banu Sahin Yildiz, Mustafa Yildiz and Ibrahim Akin
Affiliation:
Keywords: Drug-eluting stent, stent thrombosis, thienopyridines, proton pump inhibitors.
Abstract: Adenosin diphospat (ADP) plays a crucial role in thrombus formation. Therefore its inhibition can control excess platelet generation to prevent cardiovascular events in patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI). One of ADP’s target receptors, P2Y12 has a limited tissue distribution and is therefore an attractive pharmacological target. Thienopyridines are class of drugs that specifically and irreversibly inhibit the P2Y12 receptor. Three generations exist and in most patients, they are administered in combination with aspirin. Because of possible gastro-intestinal toxicity, a proton pump inhibitor (PPI) is often concomitantly prescribed. However, several studies suspect an interaction between thienopyridines (in particular with clopidogrel) and PPIs which decreases the inhibition of platelet formation and thus enhances the risk for cardiac events. In this review, a concise overview of pharmacokinetic and pharmacodynamic properties of all thienopyridines is given and a critical discussion of the presumed interaction with PPIs is provided.
Export Options
About this article
Cite this article as:
Yildiz Sahin Banu, Yildiz Mustafa and Akin Ibrahim, Interaction between Thienopyridines and Proton Pump Inhibitors, Cardiovascular & Hematological Disorders-Drug Targets 2014; 14 (3) . https://dx.doi.org/10.2174/1871529X14666140823121002
DOI https://dx.doi.org/10.2174/1871529X14666140823121002 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of Diabetes on Cardiac and Vascular Disease: Role of Calcium Signaling
Current Medicinal Chemistry Clinical Use of Intracoronary Gene Transfer of Fibroblast Growth Factor for Coronary Artery Disease
Current Gene Therapy Diabetes Mellitus: Novel Insights, Analysis and Interpretation of Pathophysiology and Complications Management with Imidazole-Containing Peptidomimetic Antioxidants
Recent Patents on Drug Delivery & Formulation Neuro-Clinical Signatures of Language Impairments after Acute Stroke: A VBQ Analysis of Quantitative Native CT Scans
Current Topics in Medicinal Chemistry Choice of Antihypertensive Treatment in Subjects with Pre-Diabetes. Is There a Dream After the Navigator
Current Vascular Pharmacology MicroRNAs in the Management of Heart Failure
Current Medicinal Chemistry Nanocarriers for Tracking and Treating Diseases
Current Medicinal Chemistry New and Promising Chemotherapeutics for Emerging Infections Involving Drug-resistant Non-albicans Candida Species
Current Topics in Medicinal Chemistry The Role of β-Amyloid Protein in Synaptic Function: Implications for Alzheimers Disease Therapy
Current Neuropharmacology Antioxidant Activity of Galantamine and Some of its Derivatives
Current Medicinal Chemistry Therapeutic Management Strategies for Type 2 Diabetes
Current Diabetes Reviews Antiplatelet Treatment in Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Carbon Monoxide - A Toxic Gas on the Edge to Clinical Application (Guest Editor: Rene Schmidt)]
Current Pharmaceutical Biotechnology Cardiovascular Health vs Cardiovascular Risk A 2011 Update: Cardiovascular Risk Stratification, the Basis to Reach Therapeutic Goals
Current Hypertension Reviews Effect of Antenatal Steroids on Haemodynamics in the Normally Grown and Growth Restricted Fetus
Current Pediatric Reviews Use of Antihistamines in Ocular Therapy
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Association of Selected Adipocytokines and Inflammatory Markers on Body Mass Index in Type 2 Diabetes Patients in Saudi Arabia and as Risk Factors to Cardiovascular Disease
Current Diabetes Reviews Preventing Vascular Graft Failure: Endothelial Cell Seeding and Tissue Engineering
Vascular Disease Prevention (Discontinued) Oligonucleotide-Based Molecular Therapy for Restenosis after Angioplasty
Current Drug Targets A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure
Current Vascular Pharmacology